Re: Vascepa & AMRN
miljenko >> as I see there should not be increase.[sales] My view is wrong, I can live with it, but I will not change bit of it. ... should be OTC drug
There is no question that a sound public policy argument can be made that EPA should be OTC. BUT it is not. FDA approved it, and expanded the label. Vascepa is supported by multiple patents that have neither been invalidated* nor expired.
Given this fact situation, sales WILL increase, likely to billions as most people on statins take Vascepa too.
Thus, there is a valid investment case to be made. IF the patents hold, it is all about valuation, valuation, and valuation. :-) It is not a cheap stock.
Jim
* There is a pending case to invalidate for obviousness, a loser IMO. Trial 1/13/2020
Market Data 
Markets 
AI
